Abstract
Pathological remodelling of the myocardium, including inflammation, fibrosis and hypertrophy, in response to acute or chronic injury is central in the development and progression of heart failure (HF). While both resident and infiltrating cardiac cells are implicated in these pathophysiological processes, recent evidence has suggested that endothelial cells (ECs) may be the principal cell type responsible for orchestrating pathological changes in the failing heart. Epigenetic modification of nucleic acids, including DNA, and more recently RNA, by methylation is essential for physiological development due to their critical regulation of cellular gene expression. As accumulating evidence has highlighted altered patterns of DNA and RNA methylation in HF at both the global and individual gene levels, much effort has been directed towards defining the precise role of such cell-specific epigenetic changes in the context of HF. Considering the increasingly apparent crucial role that ECs play in cardiac homeostasis and disease, this article will specifically focus on nucleic acid methylation (both DNA and RNA) in the failing heart, emphasising the key influence of these epigenetic mechanisms in governing EC function. This review summarises current understanding of DNA and RNA methylation alterations in HF, along with their specific role in regulating EC function in response to stress (e.g. hyperglycaemia, hypoxia). Improved appreciation of this important research area will aid in further implicating dysfunctional ECs in HF pathogenesis, whilst informing development of EC-targeted strategies and advancing potential translation of epigenetic-based therapies for specific targeting of pathological cardiac remodelling in HF.

Keywords Epigenetics · Endothelial cells · DNA methylation · RNA methylation · Heart failure

Introduction
Heart failure (HF) is a complex clinical syndrome arising from any structural or functional abnormality, resulting in inadequate cardiac output to support physiological demand. HF is the leading cause of hospitalisation in patients aged > 65 years, carrying considerable economic cost and regarded as a major public health burden [1]. The HF syndrome is classified according to ejection fraction, natriuretic peptide levels and presence of structural heart disease and diastolic dysfunction into three subtypes: HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF) and HF with mid-range ejection fraction (HFmrEF) [2]. In the developed world, HF prevalence is ~ 1–2% of the adult population, but rises to > 10% after 70 years of age [2], and alarmingly, is predicted to increase by ~ 50% by 2030 due to an ageing population and increased prevalence of comorbidities including obesity, diabetes and hypertension. While therapeutic advances are encouraging, in particular for acute cardiovascular events, the mortality rate for HF patients remains high with 14% mortality within six months of diagnosis [3, 4].

HF is initiated by acute or chronic injury to the myocardium and evokes a diverse and complex array of cellular responses involving resident cardiomyocytes, fibroblasts, and endothelial cells (ECs), and infiltrating immune cells, which initially repair damaged tissue and maintain cardiac function. Over time, exaggerated wound-healing responses including cardiomyocyte hypertrophy, fibrosis and inflammation lead to aberrant remodelling and cardiac dysfunction [5–8]. Such remodelling, which manifests clinically as changes in size, shape and function of the heart, represents a key determinant of HF progression. A critical player in this HF pathogenesis is...
EC dysfunction, especially in the context of HFpEF. In addition, it is well established that pathological changes in HF are associated with altered regulation of gene expression. Over the last decade, extensive efforts have been made to define the role of epigenetic regulation, including DNA methylation, histone modifications and non-coding RNAs, in cardiac development and disease. While beneficial effects of epigenetic-modifying therapies on aberrant cardiac remodelling have been reported in several pre-clinical studies [9–12], the precise cellular targets of these agents are currently unknown. Whilst the role of DNA methylation and histone modification in cardiomyocytes, cardiac fibroblasts and immune cells has been comprehensively reviewed [13], emerging evidence suggests that modification of RNA bases, termed epi-transcriptomics, are important regulators of cellular behaviour with dys-functional changes specifically implicated in HF pathogenesis [14]. Considering the increasingly apparent crucial role that ECs play in cardiac homeostasis and disease and predominant emphasis on epigenetic regulation in other cardiac cell types, this review will specifically focus on the role of nucleic acid methylation (both DNA and RNA) in the failing heart emphasising the key influence of these epigenetic mechanisms on EC function. For a full list of abbreviations, please see Table 1.

**Endothelial Cells in Health and Disease**

ECs line the interior of blood and lymphatic vessels, forming a metabolically active barrier between the circulation and smooth muscle, and playing a key role in the regulation of physiological processes, such as angiogenesis, wound healing, smooth muscle cell proliferation, fibrosis and inflammation [15]. The endothelium displays diverse structural and functional heterogeneity which adapts to the requirements of the host organ [16]. Growth of the vasculature occurs early in development with EC differentiation forming a primitive vascular network which is influenced by local environment and neighbouring cells, resulting in generation of ECs with tissue-specific functionality [17]. Regulation of vascular tone by ECs ensures appropriate delivery of blood to specific organs which is responsive to various stimuli, including shear stress, temperature and medications, and is largely mediated by nitric oxide (NO) and endothelium-dependent hyperpolarising factor (EDHF) [18, 19]. Disruption in normal physiology, due to factors such as hyperlipidaemia, physical inactivity, obesity, age, hypertension and poor diet [20], may result in EC dysfunction, reducing the ability of these cells to maintain cardiovascular homeostasis [21]. Specifically, oxidative stress (e.g. due to increased generation of reactive oxygen species [ROS] or reduced levels of endogenous antioxidants) and inflammation may lead to abnormal NO metabolism and bioavailability, resulting in characteristic imbalance observed in dysfunctional ECs [22]. This pathogenic microenvironment initiates a series of damaging events (such as cytokine activation and leukocyte adhesion), which promote vascular permeability and infiltration of inflammatory mediators and oxidised lipoproteins, leading to impaired integrity of the vascular wall, smooth muscle cell proliferation, inflammation and atherosclerosis [20].

It is well established that EC dysfunction plays a central role in HF development and progression [23], whilst EC paracrine signalling (e.g. NO, prostacyclin, angiotensin II [AngII] and endothelin 1 [ET-1]) is a critical modulator of cardiomyocyte survival, growth and contractility, and cardiac fibroblast function and extracellular matrix (ECM) turnover. Indeed, recent focus on ECs as the leading cellular driver of cardiac dysfunction in HFpEF represents a paradigm shift towards understanding a complex disease which currently has no clinically effective treatment that can reduce mortality [24]. A particular feature of HFpEF appears to be cardiac microvascular dysfunction [25–27]. For example, reduced coronary microvascular density, or microvascular rarefaction, was reported in myocardial tissue from HFpEF patients which was associated with increased fibrotic burden [25]. While the precise underlying mechanisms contributing to microvascular rarefaction in HFpEF are not fully understood, several factors are implicated, including loss of EC mass, due to apoptosis or differentiation, EC angiogenic dysfunction and inflammation [26–28]. Indeed, the prospective multi-centre, PROMISS-HFpEF trial reported that microvascular dysfunction was associated with disease severity in the absence of significant macrovascular coronary artery disease [27]. Collectively, these studies highlight EC dysfunction and loss of vascular structure likely drivers of myocardial hypoxia and consequent aberrant remodelling in HF.

Mounting evidence indicates that epigenetic pathways play a vital role in regulating key EC genes, such as NOS3 (eNOS) [29], and are responsive to a wide range of intrinsic and environmental stimuli, including those involved in the pathogenesis of HF. Whilst it is widely appreciated that modification of histone proteins and regulation through non-coding RNAs contribute to EC homeostasis and dysfunction, this review will focus on the emerging role of DNA and RNA methylation in HF and their specific influence on EC function in response to pathological stimuli such as hyperglycaemia and ischaemia.

**DNA Methylation in Heart Failure**

DNA methylation is a key epigenetic modification which involves covalent attachment of a methyl group to the carbon 5’ position of a DNA cytosine ring resulting in the formation of 5-methylcytosine (5mC). This process mainly occurs in palindromic cytosine-(phosphate)-guanine dinucleotides ( CpGs) throughout the genome, with ~10% of all CpGs clustered together in regions known as CpG islands (CGI). CGIs are
on average a thousand base pairs in length, have GC-rich content, and are associated with ~70% of annotated mammalian promoters [30–32]. DNA methylation is mediated by DNA methyltransferase (DNMT) enzymes (DNMT1, DNMT3A and DNMT3B) using S-adenosylmethionine (SAM) as the methyl donor. DNMT1 is involved in the maintenance of established DNA methylation through preferentially binding to hemi-methylated DNA, allowing daughter cells

| Abbreviations | Description |
|---------------|-------------|
| 5aza | 5-Azacytidine |
| 5azadC | 5-Aza-2-deoxycytidine |
| 5hMeC | 5-Hydroxymethylcytosine |
| 5MeC | 5-Methylcytosine |
| ADK | Adenosine kinase |
| ALKBH5 | Alkylation repair homologue 5 |
| AngII | Angiotensin II |
| C38 | Cytosine 38 |
| CGI | CpG islands |
| CpG | Cytosine-(phosphate)-guanine dinucleotide |
| CRISPR | Clustered regularly interspaced short palindromic repeats |
| DCM | Dilated cardiomyopathy |
| DNA | Deoxyribonucleic acid |
| DNMT | DNA methyltransferase |
| DNMT1 | DNA methyltransferase 1 |
| DNMT3A | DNA methyltransferase 3A |
| DNMT3B | DNA methyltransferase 3B |
| EC | Endothelial cell |
| ECFC | Endothelial colony-forming cell |
| ECM | Extracellular matrix |
| EDHF | Endothelium-dependent hyperpolarising factor |
| eIF | Eukaryotic initiation factor |
| EndoMT | Endothelial to mesenchymal transition |
| eNOS | Endothelial nitric oxide synthase |
| EPCs | Endothelial progenitor cells |
| ET-1 | Endothelin 1 |
| EZH2 | Enhancer of zeste homologue 2 |
| F6A | N6-Formyladenosine |
| FTO | Fat mass and obesity-associated protein |
| HCAEC | Human coronary artery macrovascular endothelial cells |
| HCMV | Human coronavirus macrovascular endothelial cells |
| HF | Heart failure |
| HFmrEF | HF mid-range ejection fraction |
| HFpEF | HF with preserved ejection fraction |
| HFpEF | HF with preserved ejection fraction |
| HFpEF | HF with preserved ejection fraction |
| HFpEF | HF with preserved ejection fraction |
| HFpEF | HF with preserved ejection fraction |
| HIF | Hypoxia inducible factor |
| hm5C | 5-Hydroxymethylcytosine (RNA) |
| hm6A | N6-Hydroxymethyladenosine |
| HMEC | Human microvascular endothelial cell |
| HMEC | Human microvascular endothelial cell |
| HNRNP | Heterogeneous nuclear ribonucleoprotein |
| HREC | Diabetic human retinal endothelial cell |
| IGF2BP1 | Insulin-like growth factor 2 mRNA-binding proteins 1–3 |
| IncRNA | Long non-coding RNA |
| MeCP | Methyl-CpG-binding protein |
| METTL3 | Methyltransferase-like 3 |
| MECC | Methyltransferase-like 3 |
| MEC | Murine cerebral endothelial cell |
| MBD | Methyl-CpG-binding domain protein |
| MCEC | Murine cerebral endothelial cell |
| m5C | 5-Methylcytosine (RNA) |
| m6A | N6-Methyladenosine |
| m7G | N7-Methylguanosine |
| mRNA | Messenger RNA |
| MIF | Melanoma inhibitory factor |
| NOX | NADPH oxidase |
| NSUN | NOL1/NOP2/sun domain |
| PECAM | Platelet endothelial cell adhesion molecule |
| Ppdc2a | Proline-rich coiled-coil 2A |
| R7W-MP | Cell-penetrating mimetic peptides |
| R7WMP | Cell-penetrating mimetic peptides |
| RNA | Ribonucleic acid |
| RNAi | RNA interference |
| ROS | Reactive oxygen species |
| rRNA | Ribosomal ribonucleic acid |
| SAM | S-Adenosylmethionine |
| siRNA | Small interfering RNA |
| TAC | Transaortic constriction |
| TGFB2 | Transforming growth factor B2 |
| TNFα | Tumour necrosis factor alpha |
| tRNA | Transfer RNA |
| Tsp-1 | Thrombospondin-1 |
| UTR | Untranslated terminal region |
| VDAC1 | Voltage-dependent anion-selective channel 1 |
| VE | Vascular endothelial |
| VEGF | Vascular endothelial growth factor |
| vWF | Von Willebrand factor |
| WTAP1 | Wilms' tumour-associated protein 1 |
| YTH | YT521-B homology |
to retain their parent cells’ methylation profile during cell division [33], whilst DNMT3A and DNMT3B mediate de novo DNA methylation. These enzymes are highly expressed in early embryonic cells, when the majority of programmed de novo methylation events occur, and become downregulated after differentiation and in adult somatic tissues [34].

Regulation of gene expression by DNA methylation is primarily associated with transcriptional repression, occurring in the promoter region either directly or indirectly (Fig. 1). DNA methylation can directly interfere with the transcription factor binding to recognition sites in the promoter region [35]. Several transcription factors, such as the cyclic AMP-dependent activator CREB, HIF and NF-κB, recognise sequences containing CpG residues, and the binding of which to the promoter region is inhibited by methylation [35]. Indirect inhibition of gene expression can be due to recruitment of methyl-CpG-binding proteins, such as methyl-CpG-binding protein (MeCP) 1 and 2 and methyl-CpG-binding domain proteins (MBD1–4), to methylated DNA, promoting formation of a repressed chromatin state through interaction with co-repressor complexes (including components of other chromatin-modifying elements, histone deacetylases and histone methyltransferases). Interestingly, DNA methylation can also occur at intergenic regions and in gene bodies, with studies portraying a positive association between methylation and gene expression [36, 37] (Fig. 1). As with all epigenetic mechanisms, DNA methylation is dynamic in nature and can be enzymatically removed through oxidation of 5MeC to 5-hydroxymethylcytosine (5hMeC) by the ten-eleven translocation (TET) family of enzymes (TET1–3) (Fig. 1). Indeed, 5hMeC itself can act in a functional capacity by regulating gene expression rather than simply representing an intermediate breakdown product of 5MeC [38, 39].

A key role for DNA methylation in HF is becoming increasingly apparent, with numerous in-depth methylation profiling studies conducted to determine altered DNA methylation patterns in the heart and indicating key associations with cardiac disease and dysfunction across the different HF

![Fig. 1 Gene regulation by DNA methylation and demethylation.](image)

- **a** Cytosine residues (C) are methylated to 5-methylcytosine (MeC) under enzymatic action of DNMT (DNA methyltransferase) enzymes using SAM as a cofactor. Conversely, methylation marks can also be removed through demethylation; removal of methylated cytosines can be enzymatically carried out by the ten-eleven translocation (TET) enzymes, which oxidize MeC to 5-hydroxymethylcytosine (5hmC) and other breakdown products including 5-formylcytosine (5fC) and 5-carboxycytosine (5caC).
- In the promoter region (b), increased DNA methylation prevents transcription factor (TF) and RNA polymerase II (RNAPolII) binding to DNA and also recruits methyl-CpG-binding proteins (MeCP) and methyl-CpG-binding domain protein (MBD) proteins resulting in gene silencing. Removal of 5MeC from the promoter region therefore facilitates transcription. In the gene body (c), positive association has been demonstrated between increased methylation and transcriptional activation and elongation. Removal of 5MeC from the gene body therefore is associated with transcriptional repression.
aetiologies [40–46]. Further to the first reported alterations in DNA methylation in patients with end-stage HF [40, 41], several major studies have specifically focussed on profiling DNA methylation changes in dilated cardiomyopathy (DCM) [42–44, 47]. Increases in CGI methylation in both LY75 and ADORA2A were identified in DCM patients, whilst reduced expression of these genes promoted cardiac dysfunction and HF in zebrafish [42]. DNA hypermethylation was also found to be predominant in DCM, with >90% of 158 differentially expressed genes associated with altered methylation patterns in their promoter regions, with further subtractive and computational analysis revealing four genes, TK1, CLDN5, AURKB and BTNL9, displaying both hypermethylation in their gene promoter and decreased expression in this setting [43]. Similarly, increased DNA methylation was reported in the left ventricle of DCM patients, highlighting several genes demonstrating an inverse relationship between methylation and expression (e.g. decreased methylation and increased expression of HAND1 and Tbx5, increased methylation and reduced expression of FGF8 and DNAJC10) [47]. Interestingly, this particular study utilised right ventricular tissue from DCM patients as a proxy for normal cardiac tissue with meta-analysis of methylome data from the NIH Roadmap Epigenomics Project revealing similar methylation profiles between right ventricular samples from their DCM cohort and normal left ventricle [47]. Other groups have employed multi-omics approaches to identify epigenetic susceptibility regions and novel biomarkers linked to myocardial dysfunction in DCM. For example, one study identified 217 methylated regions and novel biomarkers linked to myocardial dysfunction in DCM patients and decreased expression in this setting [43]. Similarly, increased DNA methylation was reported in the left ventricle of DCM patients, highlighting several genes demonstrating an inverse relationship between methylation and expression (e.g. decreased methylation and increased expression of HAND1 and Tbx5, increased methylation and reduced expression of FGF8 and DNAJC10) [47]. Interestingly, this particular study utilised right ventricular tissue from DCM patients as a proxy for normal cardiac tissue with meta-analysis of methylome data from the NIH Roadmap Epigenomics Project revealing similar methylation profiles between right ventricular samples from their DCM cohort and normal left ventricle [47]. Other groups have employed multi-omics approaches to identify epigenetic susceptibility regions and novel biomarkers linked to myocardial dysfunction in DCM. For example, one study identified 217 methylation sites that where altered between control and DCM patients which were detectable and conserved in both peripheral blood and cardiac tissue, specifically indicating hypomethylation of 5′-flanking CpGs of both NPPA and NPPB associated with elevated expression [44]. In the context of ischaemic cardiomyopathy (ICM), differential DNA methylation has been linked with differences in gene expression compared to non-ischaemic cardiomyopathy, indicating that ICM correlates with relative hypermethylation of promoter-associated CGIs associated with repression of genes involved in oxidative metabolism [45]. Indeed, across different HF aetiologies (including DCM, ICM and hypertrophic obstructive cardiomyopathy), 195 unique DNA methylation alterations have been identified in cardiac tissue in combination with associated gene changes [46]. When compared to normal cardiac tissue, subsequent gene expression analysis revealed 7 genes (4 hypermethylated [Hey2, Msrl, Myom3, Cox17], 3 hypomethylated [Palp1, Ctgf, Mmp2] and 3 microRNAs [1 hypermethylated, mir-24-1; 2 hypomethylated, mir-21, mir-155]), with significantly altered levels consistent with the direction of methylation identified in the particular HF patient sub-group [46]. There is also increasing evidence suggesting that 5hmC generated by the action of TETs may play a functional role in remodelling processes in the heart [48, 49]. Collectively, these studies demonstrate that altered DNA methylation profiles are evident in HF, highlighting the likely important role of this key epigenetic modification in disease pathogenesis. Indeed, this is underlined by reports of beneficial effects of both nucleosidal (5-azacytidine [5aza] and 5-aza-2′-deoxycytidine [5azaC]) and non-nucleosidal (RG108) inhibitors of DNA methylation across different preclinical models of HF, including myocardial infarction (MI) [50], pressure overload/hypertension [9, 10] and catecholamine stimulation [51], which appear to exert differential anti-hypertrophic and anti-fibrotic actions independently of cardiac stress. While the precise mechanisms underlying such cardioprotective effects of DNA methylation inhibitors remain to be determined, these agents show clear potential for therapeutic targeting of pathological cardiac remodelling in HF.

**Role of DNA Methylation in Endothelial Cells**

While DNA methylation changes have been predominantly examined in both clinical and preclinical cardiac tissue containing a mixed population of cells, a major recent focus in the field is towards identifying relative alterations in individual cell types and their contribution to cardiac dysfunction in HF. The majority of such in vivo studies have primarily focussed on DNA methylation changes in cardiomyocytes [10, 52, 53], with one group suggesting that regulation of disease-associated genes (e.g. CTGF, NPPA and NPPB) in cardiomyocytes sorted from end-stage HF patients may rather occur primarily through alteration of histone signatures [52]. A small number of studies have explored DNA methylation changes in the other cardiac cell populations in response to injury. With regard to ECs, which represent the most abundant cell type in the heart, it is well known that several EC-specific genes, such as NOS3 (encodes eNOS), PECAM1, CD31, vascular endothelial growth factor (VEGF) receptor 2 (KDR), von Willebrand factor (vWF) and vascular endothelial (VE)-cadherin (CDH5), display differential DNA methylation profiles in their promoter regions [54]. Several groups have studied the role of DNA methylation in the differentiation of ECs from embryonic stem cells, with particular interest in the potential application of epigenetic priming to improve efficiency [55, 56]. DNA methylation is also altered in ECs during ageing (genome instability/senescence) and upon exposure to high-glucose conditions (hyperglycaemia) or reduced oxygen supply (hypoxia/ischaemia). This review will specifically focus on DNA methylation alterations in ECs in the context of hyperglycaemia and ischaemia (Table 2), which are major drivers of cardiac remodelling and dysfunction associated with HF.
Hyperglycaemia-Induced Endothelial Cell Dysfunction

Exposure of ECs to increased glucose levels leads to disruption of normal physiology, promoting initiation and retention of a pathophysiological state [76–78]. An important aspect of EC function is their ability to promote angiogenesis, which involves proliferation, migration, growth, differentiation and critical cell signalling events [79], and underlies tissue homeostasis and repair. In particular, diabetes-associated hyperglycaemia is known to cause diabetic cardiomyopathy, which appears to be driven by EC dysfunction [80]. Unlike histone modifications, whose role in diabetic ECs is well established [81, 82], the impact of DNA methylation in this setting is less well explored. However, several studies indicate a link between DNA methylation status in high-glucose exposed ECs and intrinsic function [57, 59, 60, 83]. For example, gene ontology analysis of transcriptomic data from ECs isolated from ischaemic muscles of diabetic or hyperlipidaemic mice highlighted a number of genes involved in pathways directing cell proliferation, growth and adhesion, cell-cell signalling and nutrient responses which displayed parallel changes in expression and promoter cytosine methylation [59]. Another report indicated that two umbilical vein EC lines, human umbilical vein ECs (HUVECs) and Ea.hy926 ECs exposed to high glucose levels displayed reduced DNA methylation at their promoter regions together with activation of transforming growth factor B2 (TGFβ2) signalling, which is strongly implicated in the pathophysiology of diabetes and associated organ fibrosis [57]. Confirmation of an emerging key role for global gains in DNA methylation in mediating EC functional response to hyperglycaemia was provided by a report that hyperproliferation in diabetic human retinal ECs (HRECs) was attenuated by co-culture with the nucleosidal DNA methylation inhibitor, 5aza, in association with reduced pro-angiogenic VEGF expression and restoration of endogenous antioxidant levels [58]. Of further relevance to diabetic retinopathy (DR), hypermethylation at the promoter of polymerase γ-1 (POLG), involved in DNA replication, was demonstrated in both diabetic retinal tissue and cultured bovine retinal ECs [61]. Additional alterations in DNA methylation of multiple genes in parallel with atypical tissue morphology, actin organisation and barrier function have been reported in ECs isolated from diabetic placenta, with pathway analysis highlighting particular association with genes clustered to cell morphology and movement functions [60]. Consistent with the concept of intra-and inter-EC heterogeneity [16, 84–86], arterial and venous ECs were reported to display varying sensitivity to high glucose exposure, with the former showing DNA methylation changes in 408 genes whilst the latter exhibited alterations in only 159 genes [60]. DNA methylation may also play a role in hyperglycaemia-mediated regulation of small non-coding RNAs in ECs, as human microvascular endothelial cells (HMECs) were found to show reduced methylation at the miR-200b promoter in response to high glucose, in parallel with decreased expression of both DNMT1 and DNMT3A expression, effects which were reversed upon treatment with either a miR-200b inhibitor or the methyl donor, SAM, which also restored EC function. Of direct clinical relevance, these findings where confirmed in mouse ECs isolated from diabetic wounds, whilst administration of SAM to diabetic animals limited miR200b expression and improved wound perfusion [62].

Endothelial colony-forming cells (ECFCs) are a distinct subset of endothelial progenitors that circulate in the blood and contribute to blood vessel development and repair. Their specific role in neovascularisation continues to drive interest in their therapeutic (both autologous and allogenic) potential for vascular disease [84, 87, 88]. Although it is well established that these cells are largely dysfunctional in diabetic patients [89, 90], only a small number of studies have reported alterations in their DNA methylation status following hyperglycaemic exposure [64]. One study of ECFCs isolated from diabetic placental tissue found that increased levels of PLAC8 (Placenta-Associated 8), linked with impaired proliferation and increased senescence, were correlated with reduced DNA methylation at 17 CpG sites, alterations which were reversed following RNAi depletion of PLAC8 [64], highlighting a possible role for this protein and associated DNA methylation changes in hyperglycaemia-induced ECFC dysfunction.

Further studies have linked DNA methylation with glycaemic memory [91, 92], with the idea that persistent alterations in levels of this modification may continue to drive EC dysfunction after cells are removed from a hyperglycaemic environment. In support of this suggestion and despite diabetic patients following an established treatment regime (exercise or insulin), decreased DNA methylation at the PLAC8 promoter (and increased expression) was found to persist in isolated ECFCs with impaired proliferative capacity and a senescent state [64]. Furthermore, hypermethylation of the POLG1 promoter and increased DNMT activity in high glucose–treated HRECs persisted after reconstitution of normal glucose conditions for a 3-month period [61]. An additional and underexplored aspect of EC response to elevated glucose levels is the process of active DNA demethylation mediated by TET activity. Dysregulation of TET expression has been reported in ECFCs isolated from diabetic patients [65], whilst reduced DNA methylation, together with increased TET2 expression and elevated levels of 5hmC, at the metalloproteinase-9 (MMP9) promoter was observed in high glucose–treated HRECs. Notably, upregulation of MMP9 damages mitochondria and increases capillary cell apoptosis within the retina, thereby contributing to DR development, and siRNA knockdown of TET2 was found to attenuate increased 5hmC and MMP9 levels, thereby protecting against high glucose–induced mitochondrial damage [63].
Taken together, these studies indicate that exposure of ECs to a hyperglycaemic environment leads to alterations in their DNA methylation status which contribute to attenuation of various aspects of EC function. This includes impacting their...
ability to orchestrate normal angiogenic growth and repair under pathophysiological high-glucose conditions. Expanding these DNA methylation studies into the specific context of the heart is required, where the detrimental effects of hyperglycaemia on myocardial ECs and vasculature are well recognised. Whilst further experimentation is also required to investigate how DNA methylation alterations in response to hyperglycaemia may be specifically manipulated, their potential as novel drug targets for both vascular disease (in the case of ECFCs) and HF is clear.

**Ischaemia-Induced Endothelial Cell Dysfunction**

Lack of or restricted blood supply to myocardial tissue is central to promoting cardiac dysfunction in HF, with ischaemia and hypoxia specifically associated with enhanced ECM deposition, inflammation and cell death [93, 94]. As ECs are highly important in maintaining myocardial perfusion, they contribute to all clinical manifestations of HF. As with other cardiac cell types, ECs are susceptible to ischaemic injury which can impact their functional capacity. Hypoxia is known to impair EC integrity, resulting in increased vascular permeability and leukocyte infiltration [95]. More importantly, in the context of myocardial reperfusion, ECs can act as a double-edged sword by promoting blood flow whilst potentiating ischaemic cardiac damage through enhanced oxidative stress [96]. Indeed, it is appreciated that both hypoxia and ROS can promote alterations in DNA methylation in ECs, leading to changes in phenotype and function and disruption of vascular homeostasis.

Accumulating evidence suggests that ECs may undergo phenotypic change in response to hypoxia, known as endothelial-to-mesenchymal transition (EndoMT), in which cells adopt fibroblast-like properties. For example, both human coronary artery macrovascular (HCAEC) and HMECs were reported to show a mesenchymal phenotype after 72 h in 1% oxygen (morphological changes, reduced CD31, elevated SNAIL, SLUG, TWIST, S100A4, and α-smooth muscle actin). This was associated with loss of EC phenotype and reduced expression of RASAL1 due to increased DNMT3A-mediated CpG methylation in the promoter region [67], as previously shown in myocardium of end-stage HF patients [49]. Loss of vascular support in the heart due to EndoMT ultimately leads to enhanced myocardial hypoxia, thereby promoting further EndoMT, vascular loss and pathological cardiac remodelling. As such, retaining the EC phenotype through targeting DNA methylation may represent a novel approach to attenuate hypoxia-induced EndoMT in HF.

In response to hypoxia, activation of HIF-dependent EC signalling facilitates an adaptive angiogenic response to low environmental oxygen which appears to involve DNA methylation changes. For example, HUVECs cultured under hypoxia (0.5% oxygen) for 2 days demonstrated increased intracellular adenosine levels due to HIF-dependent reduction of adenosine-metabolising enzyme adenosine kinase (ADK). This was associated with increased angiogenic capacity and reduced DNMT activity and global hypomethylation at the promoter regions of key angiogenesis genes, including KDR, NOS3, GATA4 and SEMA5 [68]. In contrast, another study of HUVECs maintained in hypoxia for 16 h reported increased DNA methylation at the 5′-flanking region of NOS3 that contains 13 CpG elements, leading to recruitment of MBD2 and repression of eNOS expression, which was reversed by targeted siRNA knockdown together with enhanced expression of KDR [66]. Complementary analyses in Mbd2-deficient mice demonstrated increased vascular expression of eNOS and KDR expression and improved recovery from experimental hindlimb ischaemia indicated by increased capillary and arteriole density versus wild-type controls [66]. This observation could at least partly explain why patients with vascular disease respond poorly to pro-angiogenic agents as hypoxia-induced DNA methylation changes, mediated by effector proteins such as MBD2, may promote EC dysfunction. Indeed, murine cerebral ECs (MCECs) exposed to both anoxia and glucose deprivation demonstrated increased DNA methylation at the promoter of thrombospondin-1 (Thbs1), a matricellular glycoprotein which promotes anti-angiogenic actions through inhibition of VEGF/NO signalling and EC migration/proliferation, which resulted in reduced Thbs1 expression at both RNA and protein levels [69, 97–99]. Interestingly, subsequent restoration of normal oxygen and glucose conditions for 4 h led to demethylation at the Thbs1 promoter and restoration of gene expression, suggesting that these dynamic methylation changes are inherently reversible at the cellular level [69]. Conversely, culture of human dermal microvascular ECs (HMECs) in hypoxia (1% oxygen) for 24 h was shown to increase levels of THBS1, whilst treatment of normoxic ECs with hypoxic EC–conditioned media reduced EC proliferation and induced apoptosis [100]. Although this study did not investigate THBS1 methylation changes, it is likely that differential culture conditions and exposure times (e.g. anoxic and glucose starvation for 4 h [69] versus 1% oxygen and normal glucose for 24 h [100]) and use of different ECs (primary MCECs versus immortalised HDMECs) may have accounted for contrasting results. While not conclusive, this work collectively suggests that DNA methylation may play an important role in regulating pleiotropic factors, such as THBS1, in unique populations of ECs under different environmental circumstances.

In addition to oxygen levels, vascular perfusion and direction of blood flow are known to regulate DNA methylation and gene expression in ECs, with several groups highlighting an important role for DNMT1 in modulating EC function in response to shear stress and differential flow. For example,
increased nuclear DNMT1 expression together with enhanced levels of 5MeC was reported in ECs subjected to low and oscillatory shear stress using both in vitro and in vivo systems [70]. Similarly, elevated DNMT1 levels in response to perturbed blood flow were attenuated with 5aza treatment [71]. Other studies have also reported increased DNMT1-mediated DNA methylation in the context of both increased shear stress (induced in vivo by vascular occlusion or in vitro using cone and plate flow apparatus) and unidirectional flow, associated with global hypermethylation of genes associated with cellular metabolism, nucleic acid turnover and transcription [72]. Interestingly, and consistent with the previously described study, increased expression of DNMT1 observed under unidirectional flow resulted in reduced monocyte adhesion to ECs which was reversed by treatment with 5azadC in both in vitro and in vivo models [72]. Notably, when ECs maintained under shear stress were exposed to reversed flow, DNMT1 expression remained unaltered whilst monocyte adhesion to ECs was increased, prompting the authors to propose that hypermethylation under shear stress with unilateral flow may limit the arteriogenic capacity of ECs, thereby preventing hypertrophy/hyperplasia which may lead to impaired perfusion and tissue hypoxia [72]. In addition to DNMT1, other DNMT enzymes have been implicated in regulating EC function in response to altered blood flow. For example, increased DNMT3A levels are reported in HAECs subjected to disturbed flow for 2 days, linked with hypermethylation at the promoter of anti-inflammatory and anti-thrombotic, KLF4, and decreased binding and expression of myocyte enhancer factor-2 [73]. DNMT3A-mediated methylation negatively impacted on downstream functional targets of KLF4 such as NOS3, THBD and MCP1, which was rescued by treatment with pharmacological inhibitors of DNMT (RG108 and 5aza) [73]. Collectively, these studies highlight that both hypoxia and abnormal perfusion dynamics can influence DNA methylation in ECs resulting in changes to their normal physiology and behaviour, thereby promoting EC dysfunction. Whilst there is clear potential for specifically targeting this epigenetic process in ECs for treatment of HF, particularly in the context of ischaemic cardiomyopathy, further investigation is required to define underlying mechanisms.

**RNA Methylation**

While methylation of cytosines bases on DNA is an established gene regulatory mechanism in the field of epigenetics, it is increasingly appreciated that modification of RNA bases is also critical to many aspects of gene expression including RNA export, assembly, translation and stability [101]. Since these modifications can fundamentally change the RNA properties without altering the transcript sequence, this emerging field of molecular biology investigating effects of RNA modifications on cell and organ function has been termed epi-transcriptomics. Compared with DNA, the range of modifications present in RNA is much higher, with > 160 different types reported [102], which are classified into two broad categories, substitutional or non-substitutional, depending on whether the modification impacts the nucleotide sequence. The role of substitutional modifications, such as A-to-I RNA editing, in cardiovascular disease has been extensively reviewed elsewhere [103] and is not the focus of this article. Of non-substitutional RNA modifications, methylation is the most studied and prevalent, with evidence suggesting a critical role in the regulation of cellular homeostasis. Five types of RNA methylation have been identified, namely N1-methyladenosine, N6-methyladenosine (m6A), 5-methylcytosine (m5C), N7-methylguanine and 2-O-methylation. Methylation of RNA bases involves a dynamic interplay between a variety of different writer, eraser and reader proteins. This research area is attracting increased attention, largely due to the development of high-throughput sequencing technologies, which has promoted understanding of the biological role of RNA methylation in cardiac homeostasis and disease. For the purposes of this review, the role of adenine and cytosine RNA methylation in HF will be specifically discussed, emphasising the key role which these modifications play in regulating EC function.

**Adenine Methylation in Endothelial Cells and Heart Failure**

Of all RNA modifications, the addition of a methyl group at position N6 of the adenine residue to form m6A is the most characterised and abundant post-transcriptional mRNA modification in eukaryotes. The formation and removal of m6A on both coding and non-coding RNA is a dynamic process which involves several writer and eraser proteins (Fig. 2a). The formation of m6A is mediated by a multicomponent methyltransferase complex comprising methyltransferase like 3 (METTL3) and METTL14 linked with Wilms’ tumour-associated protein 1 (WTAP1) and KIAA1429 [104]. METTL3 has been identified as the catalytic core of the complex [105] which requires other essential components to efficiently recognise, localise and methylate adenosine sites on RNA, thereby enabling m6A formation [104]. Further to recent developments in transcriptome-wide m6A mapping approaches (m6A immunoprecipitation coupled with high-throughput RNA sequencing), it is now appreciated that m6A modifications of RNA are conserved in both mice and humans, showing enrichment near stop codons and untranslated terminal regions (UTR) and within internal long exons [106, 107]. In mammals, roughly 0.1–0.4% of all adenosines in cellular RNA are m6A modified and account for more than 80% of all RNA base methylations [106–108].
Similar to DNA methylation, m6A can undergo enzymatic adenosine demethylation in RNA, with two enzymes identified as playing a key role, fat mass and obesity-associated protein (FTO) and alkylation repair homologue 5 (ALKBH5). These enzymes catalyse the removal of m6A through oxidation to N6-hydroxymethyladenosine (hm6A) and N6-formyladenosine (f6A) [109], with studies demonstrating a global increase in m6A in mRNA in response to targeted deficiency of RNA methylases [110, 111]. The intermediate products of m6A removal have a relatively short half-life under physiological conditions (~3 h), and it remains to be determined if hm6A and f6A serve specific biological functions [109].

Complementary to writer (establish m6A) and eraser (remove m6A) proteins, reader proteins, located in the cytoplasm and nucleus and identified through methylated RNA pulldown coupled with mass spectrometry, can recognise and read m6A methylation marks on mRNA and mediate the effects of m6A-modified transcripts [106]. Of these, the YT521-B homology (YTH) family of proteins is the most...
common and possesses an evolutionarily conserved YTH domain, YTHDF1–3, YTHDC1 and YTHDC2, that selectively recognises and binds to m6A [106, 112, 113]. Other proteins have also demonstrated the ability to recognise and bind directly to m6A sites, including members of the heterogeneous nuclear ribonucleoprotein (HNRNP) protein family [114], eukaryotic initiation factor (eIF) 3 [115], proline rich coiled-coil 2A (PPRC2A) [116], and insulin-like growth factor 2 mRNA-binding proteins 1–3 (IGF2BP1–3) [117]. The binding of these reader proteins to m6A sites is reported to regulate various aspects of mRNA fate, including pre-mRNA splicing, mRNA stability, nuclear transport and translation [118–123].

It is now appreciated that m6A methylation regulates structural and functional properties of RNA and that this modification is essential for maintenance of cellular homeostasis. Indeed, various studies have highlighted a critical role for m6A methylation in key biological processes such as embryonic and tissue development [124, 125], control of circadian clock [126], regulation of body weight and metabolism [127, 128], learning and memory [129], spermatogenesis [111, 113], response to stress [130, 131] and cellular renewal and differentiation [132–134]. It is therefore unsurprising that dysfunctional changes in this RNA modification are associated with pathological conditions, including various cancers [135], obesity and metabolic diseases [136], neurological disorders [137] and cardiovascular diseases, such as arrhythmia [138], coronary artery disease [136] and HF [14, 139, 140]. With regard to HF, increased m6A levels have been demonstrated in hearts of patients with DCM compared to those without [139]. Specifically, 1595 methylated transcripts were identified particular to DCM that were enriched in genes associated with cardiac development, transcription and cell adhesion, and reduced in genes involved in translation and protein targeting [139]. Similarly, global levels of m6A were found to be elevated in hearts of patients with ischaemic cardiomyopathy, which was also evident in multiple experimental ischaemia models (including mice and pigs) and linked with global reduction in cardiac FTO expression [14]. However, the association of other m6A writers (Mettl3, Mettl4, Mettl14) and erasers (Alkbh5) with ICM was inconsistent and with varying cardiac expression detected at different time points post-MI [14]. Interestingly, in the context of DCM, increased levels of m6A were not associated with altered expression of FTO or METTL3 [139]. Whilst the precise molecular changes underpinning dysfunctional global m6A methylation are unclear, it is likely that variance reported in different HF aetiologies is influenced by underlying cardiac disease and risk factors mediating altered behaviour of the methylated transcripts. Indeed, this has been highlighted in the context of pressure overload, in which hearts from transaortic constricted (TAC) mice showed reduced m6A in mRNA relative to sham animals mirrored by decreased Mettl3 gene expression 2 days after surgery [139].

To better understand the functional role of global m6A changes in the heart, much research has focussed on investigating the specific importance of this modification in individual cell types. As with DNA methylation, the majority of such studies have focused on defining alterations of the m6A machinery, through gain or loss of function, in cardiomyocytes, and its subsequent impact in cardiac homeostasis and disease. For example, Fto overexpression in cardiomyocytes exposed to hypoxia in vitro led to improvement in sarcomeric function and calcium signalling, whilst Fto knockdown caused aberrant cardiomyocyte function including altered repolarisation and increased arrhythmia [14]. Interestingly, siRNA knockdown of Fto in cardiomyocytes blunted cellular hypertrophy in response to α-adrenergic stimulation [139], suggesting that impact of m6A methylation on cellular function/behaviour may be dependent upon specific environment or stress. Indeed, AAV9-targetted overexpression of Mettl3 in cardiomyocytes attenuated TAC-induced pathological cardiac remodelling (hypertrophy and fibrosis) after 2 weeks [139], whilst another group reported that transgenic overexpression of Mettl3 in cardiomyocytes did not influence TAC-induced cardiac structural and functional changes after 8 weeks, but that Mettl3 deletion in cardiomyocytes resulted in maladaptive eccentric cardiac remodelling in response to natural ageing and pressure overload [140]. Although further work is clearly required to elucidate the functional role of the cardiomyocyte m6A machinery, such studies support the concept that changes in m6A methylation of RNA may alter cellular behaviour and contribute to pathological changes.

As the majority of work to date has focused on cardiomyocytes, it is unclear whether changes in m6A levels or the enzymes that mediate this epi-transcriptomic process may regulate EC function in the healthy and/or diseased heart. Hypoxia has been previously highlighted as a key stimulus driving changes in m6A through HIF-dependent mechanisms in other cell types, including breast cancer stem cells in which ALKBH5-mediated demethylation of 3’ UTR m6A in pluripotent factors (including NANOG) is reported [141]. One study found that incubation of HUVECs in hypoxia for 16 h had no impact on FTO gene expression relative to cells exposed to normoxia, although expression of m6A components was not assessed [14]. Interestingly, however, the authors noted that mice with both transient and sustained AAV9-mediated cardiac-specific Fto expression demonstrated a higher number of CD31-positive ECs at the infarct border zone after 4 weeks post-MI. While the precise reason for this apparently enhanced angiogenic response at the border zone with FTO overexpression is unclear, it may be that cardiac manipulation of adenine demethylases induces pro-reparative or vasoprotective signalling in ECs, which could have therapeutic implications for HF where defects in the cardiac microvasculature (e.g. reduced capillary density) are an established hallmark of disease progression [25, 142, 143].
Mechanisms involved in dynamic acquisition and maintenance of cellular identity are critical for normal physiological development, whilst novel paradigms in developmental vascular biology indicate that during embryogenesis, haematopoietic stem and progenitor cells (HSPCs) are derived from a subset of ECs in the ventral wall of the dorsal aorta through a process known as endothelial-haematopoietic transition (EHT). This transitional process involves induction of a haematopoietic transcriptional programme in selected ECs resulting in tight-junction dissolution, loss of cell polarity and release into the circulation [144, 145]. As such, EHT is a complex, multi-step process that is critical for lifelong reconstitution of the blood. While the precise molecular mechanisms underlying EHT are not fully understood, it appears that m6A methylation may be critical in regulating this developmental transition. Simultaneous knockdown of mettl3 and reader protein ythdf2 in zebrafish embryos was found to prevent EHT, resulting in retention of EC phenotype characterised by increased expression of markers such as tbx20, hey2 and ephrinB2a [146]. Furthermore, addition of m6A by mettl3 near the stop codon of the notch1a mRNA transcript in ECs facilitated binding of ythdf2, resulting in mRNA decay of notch1a and acquisition of HSPC phenotype (increased expression of runx and cmyb) [146]. This highlights a mechanism by which m6A methylation during embryonic development may repress Notch signalling, which is known to prevent EHT and enable retention of EC phenotype [132, 147]. Ultimately, these findings suggest that m6A methylation is an important regulator, maintaining EC fate during development, which could be potentially exploited for treatment of HF.

**RNA Cytosine Methylation**

Similar to catalytic addition of methyl groups to cytosine residues on DNA, cytosine bases in RNA can also become methylated leading to the formation of 5-methylcytosine (m5C) (Fig. 2b). RNA methylation has been demonstrated on a variety of species including mRNA, rRNA, tRNA, snRNA, miRNA and lncRNA [148–150]. The ability to assess cytosine methylation in vitro and in vivo has been primarily facilitated through developments in methylation mapping approaches based on chemical derivatisation (bisulphite conversion or treatment with nucleosidal inhibitors e.g. 5aza) coupled with enrichment strategies (e.g. antibody-based immunoprecipitation) followed by RNA sequencing, as discussed in a recent review [148]. These approaches have been employed to identify m5C sites across different species. The abundance of m5C has been reported to range from 0.02 to 0.1% [151] with distribution found to be highly conserved in mammalian cells and tissues and enriched near the translation initiation sites of mRNAs [152–154].

Several different enzymes are responsible for the formation of m5C on RNA, including the seven-member NOL1/NOP2/Sun (NSUN) domain-containing family (NSUN1–7) and DNMT2, which utilise SAM as the methyl donor to form m5C. Whilst DNMT2 shares the same conserved catalytic motifs and a clear phylogenetic relationship as DNA methylating DNMTs [155, 156], it utilises this DNMT-like mechanism to act on RNA as a substrate to form m5C. Such RNA methyltransferase activity is demonstrated by its ability to methylate a small set of tRNAs at a specific site, cytosine 38 (C38), close to the anticodon [157], thereby increasing the tRNA stability and impacting protein translation [158, 159]. The remaining enzymes catalysing m5C belong to the NSUN family which mediate RNA methylation on the majority of RNA species through their active site bearing two catalytic cysteines [160]. Interestingly, it appears that specific levels of RNA cytosine methylation and activity of individual RNA methyltransferases may exert functional influence on cellular responses to drug treatment [161].

Formation of m5C has been shown to influence numerous aspects of RNA biology, including structure, stability and translation of mRNA [148], and biogenesis and functionality of ribosomes [162, 163]. Similar to adenine methylation, there are associated ‘m5C reader’ proteins which can mediate the activity of methylated RNA species, such as nuclear export factor ALYREF, which binds to and regulates nuclear export of mRNAs based on its m5C status [153]. Other m5C reader proteins have been described, including the m6A reader, YTHDF2, which can also recognise and bind to m5C within RNA to influence rRNA methylation. Additional putative m5C reader proteins include YTHDF1 and 3, pre-mRNA splicing factors, SF3B and NONO, and mRNA cleavage stimulation factors, CSTF1–3, which have been identified in HeLa and HEK293T cells using SILAC-based quantitative proteomics [164]. Such work has highlighted a new concept of overlap between methylation reader proteins for different RNA methylation marks. While it appears that crosstalk between adenine (m6A) and cytosine (m5C) methylation marks influences both methylation and protein expression patterns [165], it is not known whether reader protein specificity for methylation marks is evident under physiological or pathological conditions.

As with removal of 5MeC from DNA, it is now appreciated that TET enzymes are also involved in catalysing hydroxylation of m5C to hydroxy-m5C (hm5C) on RNA, including mRNA [166]. While the precise functional role of hm5C on RNA is poorly understood, recent evidence suggests that 5hmC may play an important role in post-transcriptional gene regulation in murine embryonic stem cells [167] and infection-induced myelopoiesis [168].
RNA Cytosine Methylation in Endothelial Cells and Heart Failure

Similar to adenine methylation, alterations in enzymes that mediate cytosine methylation of RNA (in particular the NSUN family) are implicated in various pathological conditions including solid and haematological malignancies [169–171], and neurodevelopmental disorders such as autosomal recessive Dubowitz syndrome [172, 173]. Notably, RNA cytosine methylation occurs more frequently in mice, and to a lesser extent in human heart and muscle tissue, compared with other tissues (such as spleen), with m5C-enriched genes linked with mitochondrial function (e.g. voltage-dependent anion-selective channel 1, VDAC1) [149]. However, unlike m6A methylation, there are relatively few reports of RNA cytosine methylation in HF. Cardiосpecific deletion of Nsun4 in mice resulted in cardiac hypertrophy after 5 weeks of age, characterised by impaired assembly of mitochondrial ribosomes and inhibition of mitochondrial translation [174]. Interestingly, pathological cardiac hypertrophy and fibrosis with preserved function was demonstrated in mice deficient in Dnmt2, associated with reduced cytosine methylation of the non-coding RNA, Rn7sk [175]. Absence of Dnmt2 in embryonic stem cells also promoted RNA polymerase II activity with enhanced cardiac cell differentiation, suggesting that DNMT2 may be an important regulator of this process through methylation of non-coding RNAs such as Rn7sk [175].

The influence of RNA cytosine methylation on EC function is becoming increasingly apparent, especially in the context of metabolic dysfunction and inflammation. For example, NSUN2 is reported to methylate ICAM-1 mRNA at 5′ and 3′ UTR in ECs exposed to pro-inflammatory mediators (tumour necrosis factor-α [TNF-α] and homocysteine), resulting in enhanced translation and protein expression both in vitro and in vivo and associated with increased leukocyte adhesion and formation of allograft arteriosclerosis, which was attenuated by genetic deficiency of NSUN2 [74]. Similarly, upregulation of NSUN2 in HUVECs exposed to hydrogen peroxide and high glucose led to increased cytosine methylation at the 5′ and 3′ UTR and coding region of SHC mRNA that was accompanied by premature senescence and enhanced expression of key proteins, such as SHC, TP53 and p16 [75]. There is also evidence to suggest that NSUN2 methylation may coordinate oxidative stress–induced senescence in epithelial carcinoma cells lines through synergistic effects with METTL3/ METTL14-mediated m6A methylation [165], although it is yet to be determined whether cooperation of different RNA methylation marks contributes to EC dysfunction in the context of cardiovascular disease.

Conclusion and Future Perspectives

Remarkable progress has been made towards understanding molecular mechanisms underlying changes in both DNA and RNA methylation in cardiovascular development and disease, especially in the context of HF. Whilst the majority of these pioneering studies assessed DNA and RNA methylation in cardiac tissue, there is now a major shift towards dissecting the relative contribution of epigenetic changes within individual cell types in HF. In this regard, ECs line the entire vasculature where they perform an essential role in maintaining homeostasis; they are particularly important in the heart where they represent the largest cell population forming an active barrier between the coronary circulation and myocardium. It is therefore unsurprising that dynamic changes in nucleotide methylation in response to injurious stimuli, such as hypoxia and metabolic dysfunction (e.g. hyperglycaemia), have been implicated in promoting EC dysfunction and HF (Fig. 3).

Beyond the scope of this review, it is appreciated that DNA and RNA methylation interact with and form complex regulatory networks with other epigenetic modifications, including those to histone tails, ATP-dependent chromatin remodelling complexes, and other noncoding RNA species (miRNAs and lncRNAs), to dynamically modulate chromatin structure and gene expression. One example of such cooperation in the context of ECM is indicated by interaction between enhancer of zeste homologue 2 (EZH2, component of polycomb repressive complex 2 and a histone methyltransferase) and DNA methylation to regulate ischaemia-induced expression of metabolic enzymes and transcription factors in the heart [45]. With specific regard to cooperation of epigenetic processes in ECs, DNA methylation has been shown to regulate expression of miRNAs and lncRNAs in hyperglycaemia, thereby impacting EC function [62, 176]. Although not specifically determined in ECs, crosstalk of epigenetic processes has also been described for RNA methylation, whereby the histone modifications [177] and non-coding RNAs [178] are reported to act as guides for depositing m6A on RNA. The role of these epigenetic mechanisms, including histone modifications [133, 179], miRNAs [180, 181], lncRNAs [182], and RNA editing [103] in regulating EC (patho)physiology are comprehensively reviewed elsewhere.

It is well established that ECs within individual organs are not homogenous, with their expression profile and activity differing depending on arterial, venous, capillary, and sinusoidal origin. Such heterogeneity includes differences in cellular morphology, production of ECM, and tight junction formation [183–185], due to physical and biochemical alterations in the relative microenvironment, with arterial and venous ECs exposed to different levels of oxygen, waste products, blood flow and pressure [186]. It is clear that EC heterogeneity supports normal physiology in organ systems with specific requirements, such as the blood-brain-barrier whose main function is protection versus the renal vasculature whose main function is filtration. Although numerous reports have indicated variable intra-organ and inter-vascular EC expression profiles, the molecular mechanisms underlying this phenomenon...
are not fully understood [60, 86, 187–189]. One study reported epigenetic changes across nine different EC types (3 of which were cardiac), confirming differential expression (of e.g. homeobox genes) in parallel with identification of EC-specific enhancers and markers of EC type, together with levels of active histone marks [189]. However, it is increasingly evident that DNA methylation may also be important in dictating EC regulation in specific EC populations under basal and pathological conditions, whilst noting that most of the available data for nucleic acid methylation have been produced using non-cardiac ECs, such as HUVECs or HRECs. Due to known heterogeneity of ECs, these cell lines may not be representative models for investigating DNA methylation in the context of the heart [190], so given the emerging role of ECs in HF, it is critical that focused analyses of DNA methylation are conducted across subsets of cardiac ECs. It is particularly important to assess methylation changes in ECs exposed to relevant pathophysiological stresses, such as hyperglycaemia, hypoxia, and ischaemia, and translating this to the development and clinical application of epigenetic targeting of dysfunctional ECs for HF therapy.

The attraction of these epigenetic changes from a therapeutic perspective lies in their inherently reversible nature along with potential for pharmacologically targeting and modulation.

There are currently two inhibitors of DNA methylation, 5aza and 5azadC, clinically approved for treatment of haematological malignancies such as acute myeloid leukaemia and myelodysplastic syndromes. Whilst both of these agents beneficially impact pathological cardiac remodelling in preclinical models of HF [9, 50, 51], their precise mechanisms of action in this setting remains to be determined. However, the ability of these agents to influence DNA methylation in ECs both in vitro and in vivo in different vascular pathologies, suggests that they could act directly on ECs to attenuate pathological cardiac remodelling. Similarly, due to accumulating evidence supporting dysfunctional RNA methylation as a key aspect of disease pathophysiology, much effort has been directed towards the design of pharmacological agents that can actively target writer and eraser proteins mediating epi-transcriptomic modifications. Indeed, in-silico discovery and subsequent characterisation has facilitated identification of small-molecule compounds that efficiently bind to and activate the METTL3-METTL14 and WTAP writer complex, leading to increased levels of m6A in cellular mRNA and rRNA [191]. In addition, drugs with known therapeutic action may also influence methylation of RNA species. For example, meclofenamate sodium, a non-steroidal anti-inflammatory agent used to inhibit prostaglandin synthesis for treatment of arthritis, also selectively inhibits FTO.
TNF-α-reduced cytosine methylation at DMRs in the date precise underlying mechanisms, including specific HF is promising, further research is clearly required to eluci-
date whilst minimising adverse off-target effects.

an exciting platform for delivery of epigenetic-modifying diabetic cardiomyopathy [198]. Such technology represents resulting in improved myocardial function in a rat model of calcium phosphate nanoparticles were shown to be more convenient to use with increased drug bioavailability, which show improved outcomes in oncology patients [196]. One of the major limitations of currently approved DNMT inhibitors is their ability to reduce global DNA methylation rather than promoting demethylation at specifically targeted genomic loci. However, this is being addressed through advancements in CRISPR-Cas9 technology facilitating Cas9 fusion with epigenome-editing enzymes (e.g. TETs, DNMTs) to induce site-specific changes in methylation. This concept has demonstrated positive preliminary results in the context of diabetic kidney disease in which Cas9 fusion with TET1 specifically reduced cytosine methylation at DMRs in the TNF-α gene leading to enhancement of expression [197]. As such, this approach shows great potential and could also be exploited to induce DNA methylation at specific genomic loci by coupling Cas9 to DNMT enzymes to induce methylation-specific gene silencing. There has also been major development of novel strategies for cardiac-specific drug delivery, including peptide-loaded nanoparticle delivery via inhalation. For example, cell-penetrating mimetic peptides (R7W-MP) loaded to calcium phosphate nanoparticles were shown to be more efficient for cardiac-targeted delivery than other routes of administration including oral, intravenous or intraperitoneal, resulting in improved myocardial function in a rat model of diabetic cardiomyopathy [198]. Such technology represents an exciting platform for delivery of epigenetic-modifying agents (e.g. small-molecule inhibitors, non-coding RNAs) directly to the myocardium thereby maximising their therapeutic action whilst minimising adverse off-target effects.

In conclusion, whilst the future of epigenetic therapy for HF is promising, further research is clearly required to elucidate precise underlying mechanisms, including specific involvement of nucleic acid methylation in EC dysfunction and its contribution to pathological cardiac remodelling. Answering such fundamental questions is likely to inform development of EC-targeted strategies and translation of epigenetic-modifying therapies for clinical benefit in HF.

Acknowledgements The authors’ work is supported by the British Heart Foundation and Heart Research UK.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011;124(25):2865–73.

2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.

3. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996–1004.

4. Mehta PA, Dubrey SW, McIntyre HF, Walker DM, Hardman SM, Sutton GC, et al. Improving survival in the 6 months after diagnosis of heart failure in the past decade: population-based data from the UK. Heart. 2009;95(22):1851–6.

5. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101(25):2981–8.

6. Takawale A, Sakamuri SS, Kassiri Z. Extracellular matrix communication and turnover in cardiac physiology and pathology. Comprehensive Physiology. 2015;5(2):687–719.

7. Adamo L, Rocha-Resende C, Prabhud SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020.

8. Kolwicz SC Jr, Purohit S, Tian R. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res. 2013;113(5):603–16.

9. Watson CJ, Horgan S, Neary R, Glezeva N, Tea L, Corrigan N, et al. Epigenetic therapy for the treatment of hypertension-induced cardiac hypertrophy and fibrosis. J Cardiovasc Pharmacol Ther. 2016;21(1):127–37.

10. Stenzig J, Schneebberger Y, Loser A, Peters BS, Schaefer A, Zhao RR, et al. Pharmacological inhibition of DNA methylation
attenuates pressure overload-induced cardiac hypertrophy in rats. J Mol Cell Cardiol. 2018;120:53–63.
11. Spiltoir JI, Stratton MS, Cavasin MA, Demos-Davies K, Reid BG, Qi J, et al. BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. J Mol Cell Cardiol. 2013;63:175–9.
12. Kee HJ, Sohn IS, Nam KJ, Park JE, Qian YR, Yin Z, et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 2006;113(1):51–9.
13. Russell-Hallinan A, Watson CJ, Baugh JA. Epigenetics of aberrant cardiac wound healing. Comprehensive Physiology. 2018;8(2):451–91.
14. Mathiyalagan P, Adamiak M, Mayourian J, Sassi Y, Liang Y, Fortin CL, Wang Y, Nagao RJ, et al. BET acetyl-lysine binding proteins control pathological cardiac wound healing. Comprehensive Physiology. 2018;8(2):451–91.
15. Favero G, Paganelli C, Buffoli B, Rodella LF, Rezzani R. Endothelium and its alterations in cardiovascular diseases: life style intervention. Biomed Res Int. 2014;2014:801896.
16. Marcu R, Choi YJ, Xue J, Fortin CL, Wang Y, Nagao RJ, et al. Human organ-specific endothelial cell heterogeneity. iScience. 2018;4:20–35.
17. Udan RS, Culver JC, Dickinson ME. Understanding vascular development. Wiley Interdiscip Rev Dev Biol. 2012;3(2):327–46.
18. Sandoo A, van Zanten JJ, Metsios GS, Carroll D, Kitas GD. The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J. 2010;4:302–12.
19. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33(7):829–37, 37a–37d.
20. Widmer RJ, Lerman A. Endothelial dysfunction and cardiovascular disease. Glob Cardiol Sci Pract. 2014;2014:391–308.
21. Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Premer C, Kanelidis AJ, Hare JM, Schulman IH. Rethinking endothelial dysfunction as a crucial target in fighting heart failure. Mayo Clin Proc Innov Qual Outcomes. 2019;3(1):1–13.
22. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschöpe C, et al. Myocardial microvascular inflammatory endothelial dysfunction in heart failure with preserved ejection fraction. Lab Investig. 2019;99(3):371–82.
23. Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, et al. Fulminant myocarditis with myopericarditis in SARS-CoV-2 infection. Eur Heart J. 2020;41(27):2496–507.
24. Koczor CA, Lee EK, Torres RA, Boyd A, Vega JD, Uppal K, et al. Detection of differentially methylated gene promoters in failing and nonfailing human left ventricle myocardium using computation analysis. Physiol Genomics. 2013;45(14):597–605.
25. Moir M, Haas J, Svedlund S, Saraste A, Hage C, Tan RS, et al. Epigenome-wide association study identifies cardiac gene patterning and a novel class of biomarkers for heart failure. Circ Res. 2019;125(11):e1143–e1149.
26. Greco CM, Kunderfranco P, Rubino M, Larcher V, Carullo P, Collier P, et al. DNA hydroxymethylation controls cardiomyocyte gene expression in development and hypertrophy. Nat Commun. 2016;7:12418.
27. Jo BS, Koh IU, Bae JB, Yu HY, Jeon ES, Lee HY, et al. Methylome analysis reveals alterations in DNA methylation in the regulatory regions of left ventricle development genes in human dilated cardiomyopathy. Genomics. 2016;108(2):84–92.
28. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011;25(10):1010–22.
29. Sen GL, Reuter JA, Webster DE, Zhu L, Khavari PA. DNMT1 maintains progenitor function in self-renewing somatic tissue. Nature. 2010;463(7280):563–7.
30. Kim GD, Ji N, Kelesoglu N, Roberts RJ, Pradhan S. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J. 2002;21(15):4183–95.
31. Das PM, Singal R. DNA methylation and cancer. Journal of Clinical Oncology. 2004;22(22):4632–42.
32. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang Y. Genome body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell. 2014;26(4):577–90.
33. Jjingo D, Conley AB, Yi SV, Lunyak VV, Jordan IK. On the presence and role of human-body DNA methylation. Oncotarget. 2012;3(3):462–74.
34. Chapman CG, Mariani CJ, Wu F, Meckel K, Butun F, Chuang A, et al. TET-catalyzed 5-hydroxymethylcytosine regulates gene expression in differentiating colonocytes and colon cancer. Sci Rep. 2015;5:17568.
35. Wu H, Zhang Y. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell. 2014;156(1–2):45–68.
36. Movassagh M, Moyer MK, Goddard M, Bennett MR, Down TA, Foo RS. Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS One. 2010;5(11):e8564.
37. Movassagh M, Moyer MK, Knowles DA, Cordeedu L, Haider S, Down T, et al. Distinct epigenomic features in end-stage failing human hearts. Circulation. 2011;124(22):2411–22.
38. Haas J, Frese KS, Park YJ, Keller A, Vogel B, Lindroth AM, et al. Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Molecular Medicine. 2013;5(3):413–29.
39. Glazova N, Moran B, Collier P, Moravec CS, Phelan D, Glezeva N, et al. Protective role of 5-azacytidine on myocardial infarction is maintained in pressure overload-induced cardiac hypertrophy in rats. J Mol Cell Cardiol. 2018;120:53–63.
40. Saxonov S, Tschöpe C, Moyer MK, Knowles DA, Cordeedu L, Haider S, et al. Oxidative stress, aging, and diseases. Clin Interv Aging. 2013;8(3):413–29.
41. Movassagh M, Moyer MK, Knowles DA, Cordeedu L, Haider S, Down T, et al. Distinct epigenomic features in end-stage failing human hearts. Circulation. 2011;124(22):2411–22.
42. Glaza N, Moran B, Collier P, Moravec CS, Phelan D, Glezeva N, et al. Protective role of 5-azacytidine on myocardial infarction is maintained in pressure overload-induced cardiac hypertrophy in rats. J Mol Cell Cardiol. 2018;120:53–63.
43. Moyer MK, Knowles DA, Cordeedu L, Haider S, Down T, et al. Distinct epigenomic features in end-stage failing human hearts. Circulation. 2011;124(22):2411–22.
44. Haas J, Frese KS, Park YJ, Keller A, Vogel B, Lindroth AM, et al. Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Molecular Medicine. 2013;5(3):413–29.
45. Koczor CA, Lee EK, Torres RA, Boyd A, Vega JD, Uppal K, et al. Detection of differentially methylated gene promoters in failing and nonfailing human left ventricle myocardium using computation analysis. Physiol Genomics. 2013;45(14):597–605.
46. Meder B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Frese K, Lai A, et al. Epigenome-wide association study identifies cardiac gene patterning and a novel class of biomarkers for heart failure. Circulation. 2017;136(16):1528–44.
47. Pepin ME, Ha CM, Crossman DK, Litovsky SH, Varambally S, Barchue JP, et al. Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure. Lab Invest. 2019;99(3):371–86.
48. Glazova N, Moran B, Collier P, Moravec CS, Phelan D, Donnellan E, et al. Targeted DNA methylation profiling of human cardiac tissue reveals novel epigenetic traits and gene deregulation across different heart failure patient subtypes. Circ Heart Fail. 2019;12(3):e005765.
49. Jo BS, Koh IU, Bae JB, Yu HY, Jeon ES, Lee HY, et al. Methylome analysis reveals alterations in DNA methylation in the regulatory regions of left ventricle development genes in human dilated cardiomyopathy. Genomics. 2016;108(2):84–92.
50. Greco CM, Kunderfranco P, Rubino M, Larcher V, Carullo P, Anselmo A, et al. DNA hydroxymethylation controls cardiomyocyte gene expression in development and hypertrophy. Nat Commun. 2016;7:12418.
associated with modulation of macrophage phenotype and inhibition of fibrosis. J Cell Mol Med. 2014;18(6):1018–27.

51. Xiao D, Dasgupta C, Chen M, Zhang K, Buchholz J, Xu Z, et al. Inhibition of DNA methylation reverses norpāpinephrine-induced cardiac hypertrophy in rats. Cardiovasc Res. 2014;101(3):373–82.

52. Gilsbach R, Schwaderer M, Preissl S, Gruning BA, Schnick T, Burger L, Benes V, et al. Transcriptome analysis of human primary endothelial cells (HUVEC) from umbilical cords of gestational diabetic mothers reveals candidate sites for an epigenetic modulation of endothelial function by disturbed flow: induction of DNA hypermethylation by DNMT1. Cell Mol Bioeng. 2014;7(2):218–24.

53. Babu M, Durga Devi T, Mäkinen P, Kaikkonen M, Lesch HP, et al. Epigenetic modification of MicroRNA-200b contributes to diabetic retinopathy. Invest Ophthalmol Vis Sci. 2012;53(8):4881–90.

54. Ambra R, Manca S, Palumbo MC, Leonetti L, De Marco A, et al. Hemodynamic disturbed flow induces differentially programmed endothelial cell senescence in vitro and in vivo. Circ Res. 2014;115(1):32–43.

55. Hu CJ, Chen SD, Yang DL, Lin TN, Chen CM, Huang TH, et al. Promoter region methylation and reduced expression of thrombospordin-1 after oxygen-glucose deprivation in murine cerebral endothelial cells. J Cereb Blood Flow Metab. 2006;26(12):1519–26.

56. Zhao S, Jia T, Tang Y, Zhang X, Mao H, Tian X, et al. Reduced mRNA and protein expression levels of Tet methylcytosine dioxygenase 3 in endothelial progenitor cells of patients of type 2 diabetes with peripheral artery disease. Front Immunol. 2018;9:2859.

57. Rao X, Zhong J, Zhang S, Zhang Y, Yu Q, Yang P, et al. Loss of methyl-CpG-binding domain protein 2 enhances endothelial angiogenesis and protects mice against hind-limb ischemic injury. Circulation. 2011;123(25):2964–74.

58. Xu X, Tan X, Hulshof MS, Wilhelmi T, Zeisberg M, Zeisberg EM. Hypoxia-induced endothelial-mesenchymal transition is associated with RASAL1 promoter hypermethylation in human coronary endothelial cells. FEBS Lett. 2016;590(8):1222–33.

59. Prisco AR, Bukowy JD, Hoffmann BR, Karcher JR, Exner EC, Greene AS. Automated quantification reveals hyperglycemia inhibits endothelial angiogenic function. PLoS One. 2014;9(4):e94599.

60. O’Neill KM, Campbell DC, Edgar KS, Gill EK, Moez A, McLoughlin KJ, et al. NOX4 is a major regulator of cord blood-derived endothelial colony-forming cells which promotes post-

61. Tewari S, Zhong Q, Santos JM, Kowluru RA. Mitochondria DNA methylation and DNA methylation in the metabolic memory associated with continued progression of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011;52(8):4881–8.

62. Singh K, Pal D, Sinha M, Ghatak S, Gnyawali SC, Khanna S, et al. Role of high glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res. 2004;95(19):1909–100.

63. Knapp M, Tu X, Wu R. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. Acta Pharmacol Sin. 2019;40(1):1–8.

64. Li Y, Reddy MA, Miao F, Shannugam N, Yee JK, Hawkins D, et al. Role of the histone H3 lysine 4 methylation, SET7/9, in the regulation of NF-kappab-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem. 2008;283(39):26771–81.

65. Zhong Q, Kowluru RA. Epigenetic modification of Sod2 in the development of diabetic retinopathy and in the metabolic memory: role of histone methylation. Invest Ophthalmol Vis Sci. 2013;54(1):244–50.

66. Ross GM, Yang Y, Yang Q, Pan Y, et al. Intracellular adenosine regulates epigenetic programming in endothelial cells to promote angiogenesis. EMBO Molecular Medicine. 2017;9(9):1263–78.
86. Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Conway EM, Carmeliet P. The diversity of endothelial cells: a challenge for therapeutic angiogenesis. Genome Biol. 2004;5(2):207.

87. O’Leary OE, Canning P, Reid E, Bertelli PM, Mckeown S, Brines M, et al. The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic. Exp Eye Res. 2019;182:144–55.

88. Langford-Smith AWW, Hasan A, Weston R, Edwards N, Jones AM, Ingram DA, Lien IZ, Mead LE, Estes M, Prater DN, Derr-Yellin K, Rajasekar P, O’Neill CL, Eeles L, Stitt AW, Medina RJ, Kang H, Ma X, Liu J, Fan Y, Deng X. High glucose-induced expression profiling. Proc Natl Acad Sci U S A. 2003;100(19):10623–8.

89. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell. 2012;149(7):1635–46.

90. Wei CM, Gershovitz A, Moss B. Methylated nucleotides block 5’-terminal sequences of HeLa cell messenger RNA. Cell. 1975;4(4):379–86.

91. Rohrer A, Everts V, Rodemann HP, Meister M. Identification of new regulatory elements in the human glucocorticoid receptor gene. Mol Cell Biol. 1995;15(2):574–87.

92. Mishra M, Kowluur A. The role of DNA methylation in the metabolic disease phenotype associated with the continued progression of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2016;57(13):5748–57.

93. Watson CJ, Collier P, Tea I, Neary R, Watson JA, Robinson C, Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119(1):91–112.

94. Ogawa S, Gerlach H, Esposito C, Pasagian-Macaulay A, Brett J, Stern D. Hyposia modulates the barrier and coagulant function of cultured bovine endothelium. Increased monolayer permeability and induction of procoagulant properties. J Clin Invest. 1990;85(4):1090–8.

95. Yellon DM, Hausenloy DJ. Myocardial repertusion injury. N Engl J Med. 2007;357(11):1121–35.

96. Rodriguez-Manzanque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruea-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 2001;98(12):12485–90.

97. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer. 2009;9(3):182–94.

98. Oganesian A, Armstrong LC, Migliorini MM, Strickland DK, Bornstein P. Thrombospondin uses the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell. 2008;19(2):563–71.

99. Morgan-Rowe L, Nikitorowicz J, Shiwen X, Leask A, Tsuj I, Abraham D, et al. Thrombospondin 1 in hypoxia-conditioned media blocks the growth of human microvascular endothelial cells and is increased in systemic sclerosis tissues. Fibrogenesis Tissue Repair. 2011;4:13.
122. Zhao BS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol. 2017;18(1):31–42.

123. Roundtree IA, Luo GZ, Zhang Z, Wang X, Zhou T, Cui Y, et al. YTHDC1 mediates nuclear export of N(6)-methyladenosine methylated mRNAs. Elife. 2017;6.

124. Horiiuchi K, Kawamura T, Iwanari H, Ohashi R, Naito M, Kodama T, et al. Identification of Wilms' tumor 1-associating protein complex and its role in alternative splicing and the cell cycle. J Biol Chem. 2013;288(46):33292–302.

125. Batista PJ, Molinie B, Wang J, Qu K, Zhang J, Li L, et al. M(6)a RNA modification controls cell fate transition in mammalian embryonic stem cells. Cell Stem Cell. 2014;15(6):707–19.

126. Fustin JM, Doi M, Yamaguchi Y, Hida H, Nishimura S, Yoshida M, et al. RNA-methylation-dependent RNA processing controls the speed of the circadian clock. Cell. 2013;155(4):793–806.

127. Speakman JR. FTO effect on energy demand versus food intake. Biochem Biophys Res Commun. 2010;400(4):713–8.

128. Sun T, Wu R, Ming L. The role of m6A RNA methylation in cardiovascular homeostasis and hypertrophy. Circulation. 2019;139(4):533–41.

129. Shi H, Zhang X, Weng YL, Lu Z, Liu Y, Lu Z, et al. M(6)a methylated mRNAs. Elife. 2017;6.

130. Zhou J, Wan J, Gao X, Zhang X, Jaffrey SR, Qian SB. Dynamic mRNA modifications. Nat Rev Mol Cell Biol. 2017;18(1):31–42.

131. Tian C, Huang Y, Li Q, Feng Z, Xu Q. Mettl3 regulates osteogenic differentiation and alternative splicing of Vegfa in bone marrow mesenchymal stem cells. Int J Mol Sci. 2019;20(3).

132. Lizama CO, Hawkins JS, Schmitt CE, Bos FL, Zape JP, Cautivo et al. Impaired VE-cadherin/beta-catenin expression mediates endothelial cell degeneration in dilated cardiomyopathy. Circulation. 2003;108(13):1585–91.

133. Cleveland PM, Sansom J, Knutsson L, Karsunky H, Zou Y, et al. m6A mRNA methylation regulates alternative splicing and RNA stability. Nature. 2010;464(7289):E1; discussion E2.

134. Bertrand JY, Chi NC, Santoso B, Teng S, Stainier DY, Traver D. Haematopoietic stem cells derive directly from aortic endothelium during development. Nature. 2010;464(7285):108–11.

135. Chen MJ, Li Y, De Obaldia ME, Yang Q, Yzaguirre AD, Yamada-Inagawa T, et al. Erythroid/myeloid progenitors and hematopoietic stem cells originate from distinct populations of endothelial cells. Cell Stem Cell. 2011;9(6):541–52.

136. Gustavsson J, Mehlig K, Leander K, Lissner L, Björck L, Malone B, et al. RNA m(6)a methylation regulates the ultraviolet-induced repair of RNA. Chembiochem. 2015;16(5):752–6.

137. Legrand C, Tuorto F, Hartmann M, Liebers R, Jacob D, Helm M, et al. Statistically robust methylation calling for whole-transcriptome bisulfite sequencing reveals distinct methylation patterns for mouse RNAs. Genome Research. 2017;27(9):1589–96.

138. Dong A, Yoder JA, Zhang X, Zhou L, Bestor TH, Cheng X. Structure of human Dnmt2, an enzymatic DNA methyltransferase homolog that displays denaturant-resistant binding to DNA. Nucleic Acids Res. 2001;29(2):439–48.

139. Jurkowski TP, Jeltsch A. On the evolutionary origin of eukaryotic DNA methyltransferases and Dmnt2. PLoS One. 2011;6(11):e28104.

140. Goll MG, Kirpekar F, Maggett KA, Yoder JA, Hsieh CL, Zhang X, et al. Methylation of iRNAas by the DNA methyltransferase homolog Dmnt2. Science. 2006;311(5759):395–8.

141. Schaefer M, Poll ex T, Hanna K, Tuorto F, Meusburger M, Helm M, et al. RNA methylation by Dmnt2 protects transfer RNAs against stress-induced cleavage. Genes Dev. 2010;24(15):1590–5.

142. Schaefer M, Poll ex T, Hanna K, Tuorto F, Meusburger M, Helm M, et al. RNA methylation by Dmnt2 protects transfer RNAs against stress-induced cleavage. Genes Dev. 2010;24(15):1590–5.

143. Schaefer M, Poll ex T, Hanna K, Tuorto F, Meusburger M, Helm M, et al. RNA methylation by Dmnt2 protects transfer RNAs against stress-induced cleavage. Genes Dev. 2010;24(15):1590–5.

144. Trixl L, Lusser A. The dynamic RNA modification 5-methylcytosine and its emerging role as an epitranscriptomic mark. Wiley Interdiscip Rev RNA. 2019;10(1):e1510.

145. Huang T, Chen W, Liu J, Gu N, Zhang R. Genome-wide identification of mRNA 5-methylcytosine in mammals. Nat Struct Mol Biol. 2019;26(5):380–8.

146. Amort T, Rieder D, Wille A, Khokhlova-Cubberley D, Riml C, Trixl L, et al. Distinct 5-methylcytosine profiles in poly(a) RNA from mouse embryonic stem cells and brain. Genome Biol. 2017;18(1):1.

147. Yang Z, Yang Y, Sun BF, Chen YS, Xu JW, Liai WY, et al. 5-Methylcytosine promotes mRNA export - NSUN2 as the methyl-transferase and ALYREF as an m(5)C reader. Cell Res. 2017;27(5):506–25.

148. Trixl L, et al. Distinct 5-methylcytosine profiles in poly(a) RNA from mouse embryonic stem cells and brain. Genome Biol. 2017;18(1):1.

149. Jerilak SV, van Delf P, Mendil L, Bachman M, Smollett K, Werner F, et al. Formation and abundance of 5-hydroxymethylcytosine in RNA. Chembiochem. 2015;16(5):752–5.

150. Huber SM, van Delf P, Mendil L, Bachman M, Smollett K, Werner F, et al. Formation and abundance of 5-hydroxymethylcytosine in RNA. Chembiochem. 2015;16(5):752–5.

151. Legrand C, Tuorto F, Hartmann M, Liebers R, Jacob D, Helm M, et al. Statistically robust methylation calling for whole-transcriptome bisulfite sequencing reveals distinct methylation patterns for mouse RNAs. Genome Research. 2017;27(9):1589–96.

152. Dong A, Yoder JA, Zhang X, Zhou L, Bestor TH, Cheng X. Structure of human Dnmt2, an enzymatic DNA methyltransferase homolog that displays denaturant-resistant binding to DNA. Nucleic Acids Res. 2001;29(2):439–48.

153. Hwang YJ, Arumolam KA, Zukin RS. The emerging field of epigenetics in neurodegeneration and neuroprotection. Nat Rev Neurosci. 2017;18(6):347–61.

154. Carnevali L, Graiani G, Rossi S, Al Banchaouchoubi M, Macchi E, Quaini F, et al. Signs of cardiac autonomic imbalance and proarrhythmic remodeling in FTO deficient mice. PLoS One. 2014;9(4):e95499.

155. Knietczyk V, Riechert E, Kalinski L, Boileau E, Malovrh E, Malone B, et al. m(6)A mRNA methylation regulates cardiac gene expression and cellular growth. Life Sci Alliance. 2019;2(2).

156. Dorn LE, Lasman L, Chen J, Xu X, Hund TJ, Medvedovic M, et al. The N(6)-methyladenosine mRNA methylase METTL3 controls cardiac homeostasis and hypertrophy. Circulation. 2019;139(4):533–45.

157. Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen J, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m(6)A-demethylation of NANOG mRNA. Proc Natl Acad Sci U S A. 2016;113(14):E2047–56.

158. Schäfer R, Abraham D, Paulus P, Blumer R, Grimm M, Wojta J, et al. Impaired VE-cadherin/beta-catenin expression mediates endothelial cell degeneration in dilated cardiomyopathy. Circulation. 2003;108(13):1585–91.
162. Schosserer M, Minois N, Angerer TB, Amringer M, Dellago H, Harreither E, et al. Methylation of ribosomal RNA by NSUN5 is a conserved mechanism modulating organismal lifespan. Nat Commun. 2015;6:6158.

163. Chow CS, Lamichhane TN, Maho SK. Expanding the nucleotide repertoire of the ribosome with post-transcriptional modifications. ACS Chem Biol. 2007;2(9):610–9.

164. Dai X, Gonzalez G, Li L, Li J, You C, Miao W, et al. YTHDF2 binds to 5-methylcytosine in RNA and modulates the maturation of ribosomal RNA. Anal Chem. 2020;92(1):1346–54.

165. Fu L, Guerrero CR, Zhong N, Amato NJ, Liu Y, Liu S, et al. Tet-1 regulates the expression of ribosomal RNA. Anal Chem. 2020;92(1):1346–54.

166. Li Q, Li X, Tang H, Jiang B, Dou Y, Gorospe M, et al. NSUN2-mediated m5c methylation and METTL3/METTL14-mediated m6A methylation cooperatively enhance p21 translation. J Cell Biochem. 2017;118(9):2587–98.

167. Guallar D, Bi X, Pardavila JA, Huang X, Saenz C, Shi X, et al. RNA-LM1 binds to 5-methylcytosine in RNA and modulates the maturation of ribosomal RNA. Anal Chem. 2020;92(1):1346–54.

168. Shen Q, Zhang Q, Shi Y, Shi Q, Jiang Y, Gu Y, et al. Tet2 promotes a conserved mechanism modulating organismal lifespan. Nature. 2018;554(7690):123–7.

169. Elhardt W, Shanmugam R, Jurkowski TP, Jeltsch A. Somatic cancer mutations in the DNMT2 RNA methyltransferase alter its catalytic properties. Biochimie. 2015;112:66–72.

170. Ghahreman H, Wagner N, Baudouy D, Kiani J, Michiels JF, et al. Whole exome sequencing identifies a splicing mutation in NSUN2 as a cause of a Dubowitz-like syndrome. J Med Genet. 2012;49(6):380–5.

171. Vlahou A, Ghanbarian H, Wagner N, Baudouy D, Kiani J, Michiels JF, et al. NSUN2 is a dual function mitochondrial protein required for both methylation of 12S RNA and coordination of mitoribosomal assembly. PLoS Genet. 2014;10(2):e1004110.

172. Biswas S, Thomas AA, Chen S, Ansell JA, Chen J, Michiels JF, et al. Dnmt2/Trdm1 as mediator of RNA polymerase II transcriptional activity in cardiac growth. PLoS One. 2016;11(6):e0156953.

173. Chen T, Hsu Y, Zhang Y, Li MM, Wang M, Han W, et al. M6a RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency. Cell Stem Cell. 2015;16(3):289–301.

174. Fazi F, Fatica A. Interplay between N(6)-methyladenosine (m(6)a) and non-coding RNAs in cell development and cancer. Front Cell Dev Biol. 2019;7:116.

175. Yan MS, Marsden PA. Epigenetics in the vascular endothelium: looking from a different perspective in the epigenomics era. Arterioscler Thromb Vasc Biol. 2015;35(11):2297–306.

176. Urbich C, Kuehbacher A, Dinneler S. Role of microRNAs in vascular diseases, inflammation, andangiogenesis. Cardiovasc Res. 2008;79(4):581–8.

177. Fernández-Hernando C, Suárez Y. MicroRNAs in endothelial cell homeostasis and vascular disease. Curr Opin Hematol. 2018;25(3):227–36.

178. Weirick T, Miliutello G, Uchida S. Long non-coding RNAs in endothelial biology. Front Physiol. 2018;9:522.

179. Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med. 2012;2(1):a006429.

180. Aird WC. Phenotypic heterogeneity of the endothelium: I. structure, function, and mechanisms. Cire Res. 2007;102(2):158–73.

181. Kühn-Urgeve A, Blocki A, Franke RP, Jung F. Vascular endothelial cell biology: an update. Int J Mol Sci. 2019;20(18).

182. dela Paz NG, D’Amore PA. Arterial versus venous endothelial cells. Cell Tissue Res. 2009;335(1):5–16.

183. Sabbagh MF, Heng JS, Luo C, Castanon RG, Nery JR, Rattner A, et al. Transcriptional and epigenomic landscapes of CNS and non-CNS vascular endothelial cells. Elife. 2018;7.

184. Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018;9(1):5068.

185. Nakato R, Wada Y, Nakaki R, Nagae G, Katou Y, Tsutsumi S, et al. Comprehensive epigenomic characterization reveals diverse transcriptional regulation across human vascular endothelial cells. Epigenetics Chromatin. 2019;12(1):77.

186. Nourbissi SE, Galasso B, Sini S. Brain vascular heterogeneity: implications for disease pathogenesis and design of in vitro blood-brain barrier models. Fluids Barriers CNS. 2018;15(1):12.

187. Selberg S, Blokhina D, Aatonen M, Koivisto P, Siltanen A, Mervaala E, et al. Discovery of small molecules that activate RNA methylation through cooperative binding to the METTL3–14-WTAP complex active site. Cell Rep. 2019;26(13):3762–71.e5.

188. Huang Y, Yan J, Li Qi, Li J, Gong S, Zhou H, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 2015;43(1):373–84.

189. Schaefer M, Hagemann S, Hanna K, Lyko F. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res. 2009;69(20):8127–32.

190. Tsuchikawa LM, Fu L, Das S, Halliday C, Rakai BD, Stotz SC, et al. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. Clin Epigenetics. 2019;11(1):102.

191. Garcia-Manero G, Gore SD, Kambhampati S, Scott B, Tefferi A, et al. Discovery of small molecules that activate RNA methylation through cooperative binding to the METTL3–14-WTAP complex active site. Cell Rep. 2019;26(13):3762–71.e5.

192. Harreither E, et al. Comprehensive human cell-type methylation atlas reveals diverse transcriptional regulation across human vascular endothelial cells. Epigenetics Chromatin. 2019;12(1):77.

193. Park J, Guan Y, Sheng X, Gluck C, Seasock MJ, Hakimi AA, et al. Comprehensive epigenomic characterization reveals diverse transcriptional regulation across human vascular endothelial cells. Epigenetics Chromatin. 2019;12(1):77.

194. Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018;9(1):5068.

195. Nakato R, Wada Y, Nakaki R, Nagae G, Katou Y, Tsutsumi S, et al. Comprehensive epigenomic characterization reveals diverse transcriptional regulation across human vascular endothelial cells. Epigenetics Chromatin. 2019;12(1):77.

196. Selberg S, Blokhina D, Aatonen M, Koivisto P, Siltanen A, Mervaala E, et al. Discovery of small molecules that activate RNA methylation through cooperative binding to the METTL3–14-WTAP complex active site. Cell Rep. 2019;26(13):3762–71.e5.

197. Huang Y, Yan J, Li Qi, Li J, Gong S, Zhou H, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 2015;43(1):373–84.

198. Schaefer M, Hagemann S, Hanna K, Lyko F. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res. 2009;69(20):8127–32.

199. Tsuchikawa LM, Fu L, Das S, Halliday C, Rakai BD, Stotz SC, et al. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. Clin Epigenetics. 2019;11(1):102.

200. Garcia-Manero G, Gore SD, Kambhampati S, Scott B, Tefferi A, et al. Discovery of small molecules that activate RNA methylation through cooperative binding to the METTL3–14-WTAP complex active site. Cell Rep. 2019;26(13):3762–71.e5.

201. Huang Y, Yan J, Li Qi, Li J, Gong S, Zhou H, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 2015;43(1):373–84.